Remimazolam and Emergence Delirium in Pediatrics

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age1-6
SponsorPeking University First Hospital

About this trial

Emergence delirium is a common complication in pediatrics undergoing neurosurgery. Previous study showed that a single bolus of remimazolam was associated with lower incidence of postoperative agitation. Present study was designed to investigate if remimazolam supplemented to sevoflurane anesthesia could decrease the risk of emergence delirium in pediatrics undergoing neurosurgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Aged 1 to 6 years old

Planned to receive elective neurosurgery under general anesthesia

Expected duration of surgery > 1 hour

Disqualifiers

Allergy to benzodiazepine

Use of other sedatives within 12 hours before surgery such as benzodiazepines, propofol, chloral hydrate, etc.,

ASA classification IV or above

Unable to complete emergence delirium assessment, such as language, hearing or vision impairment.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Remimazolam

    Drug

    After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of remimazolam), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of remimazolam). The infusion is expected to stop 10 minutes before the end of the surgery.

  • Normal Saline

    Drug

    After anesthesia induction, a loading investigational drug at a rate of \[3.6\*kg\] ml/h (lasting for 5 minutes, equivalent to 0.3 mg/kg of normal saline), and then adjust the infusion rate to \[1\*kg\] ml/h (equivalent to 1 mg/kg of normal saline). The infusion is expected to stop 10 minutes before the end of the surgery.

Treatment groups

248 Participants
are divided into 2 treatment groups
Group A: Remimazolam groupExperimental treatment 1 intervention
Group B: Normal saline groupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Emergence delirium

The Cornell Assessment of Pediatric Delirium (CAPD) was used to assess delirium. It consists of a total of 8 items, with each item scored from 0 to 4. Delirium can be diagnosed when the total score is ≥ 10.

Time frame
The subjects were evaluated at 10 minutes, 20 minutes, 30 minutes after admission to PACU or before discharge

Secondary outcomes

1

Postoperative delirium

The Cornell Assessment of Pediatric Delirium (CAPD) scale was used to assess whether the subjects developed delirium. It consists of a total of 8 items, with each item scored from 0 to 4. Delirium can be diagnosed when the total score is ≥ 10.

Time frame
Delirium was assessed at 07:00~09:00 and 17:00~20:00 on the 1st, 2nd and 3rd day after surgery
2

Pain score

The FLACC behavioral rating scale was used to evaluate the pain intensity. It mainly includes five indicators: Facial Expression, Legs, Activity, Cry, and Consolability. The score is the sum of the above five indicators, ranging from a minimum of 0 to a maximum of 10. A higher score indicates more obvious discomfort and pain.

Time frame
Pain intensity was assessed at 07:00~09:00 and 17:00~20:00 on the 1st, 2nd and 3rd day after surgery
3

Sleep quality within 3 days after surgery

The Numeric Rating Scale (NRS) was used for sleep quality assessment of children by their parents/caregivers within 3 days after surgery. The scores of NRS ranging from a minimum of 0 to a maximum of 10. A lower score indicates poorer sleep quality.

Time frame
Within 3 days after surgery
4

Sleep quality 7 days after surgery and 1 month after surgery

The Tayside Children's Sleep Questionnaire (TCSQ) was adopted to assess the sleep quality 7 days after surgery and 1 month after surgery.The TCSQ consists of 10 questions, with scores ranging from a minimum of 0 to a maximum of 40. A higher score indicates poorer sleep quality.

Time frame
7 days after surgery and 1 month after surgery

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.